Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
about
Drug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy types II and IIISMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCRSpinal muscular atrophy: from gene discovery to clinical trialsSpinal muscular atrophy: development and implementation of potential treatmentsRegulation of SMN protein stabilityUtility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analysesCNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophySplicing of the Survival Motor Neuron genes and implications for treatment of SMATherapeutic strategies for the treatment of spinal muscular atrophy.SMN-inducing compounds for the treatment of spinal muscular atrophy.Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein.Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy.The importance of the SMN genes in the genetics of sporadic ALS.Therapy development for spinal muscular atrophy in SMN independent targets.Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker studySplicing therapeutics in SMN2 and APOB.Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes.Spinal muscular atrophy disease: a literature review for therapeutic strategies.Biomarkers in rare disorders: the experience with spinal muscular atrophy.Anesthesia and spinal muscle atrophy.Investigational therapies for the treatment of spinal muscular atrophy.Therapeutic approaches for spinal muscular atrophy (SMA).Perceived efficacy of salbutamol by persons with spinal muscular atrophy: A mixed methods study.Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophyTreatment of spinal muscolar atrophy with intrathecal mesenchymal cells.Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells.Spinal muscular atrophy
P2860
Q24200270-A82D8F44-A156-4938-BDC0-214AC4336C09Q24234414-846AD6FC-E784-4DA3-A01D-638CFCE92D41Q24241759-00B9208E-FFF3-471B-9D77-97CD305ADF46Q24599124-39820660-D169-439A-86B8-87471A06094CQ26824894-3D6B86AD-7B37-4987-8431-BE35076E28F9Q26861377-EE285487-D456-4C8E-8130-3401204C384DQ28304878-A3B74FC7-96EA-4E35-A732-0385219EB1C0Q28740896-BAB66B3D-55AD-4D5D-8C3D-BC3F321AE8A2Q30493891-3453F539-0E6D-44C4-8A4D-CA2E0907DCD0Q30540653-D7C84687-100E-4511-A86E-6013D41BB057Q30821687-C5C7D21D-6B2D-42A2-85B8-8515DFCF3F39Q34065993-E1D8F732-D98C-419D-8F14-8CBDDD112335Q34296140-3C72C8E0-091A-4AB7-8F57-A95CC2D3D04DQ34312156-7A2DC808-E6F1-4A12-98B7-6181ECAE6357Q34505876-4CB62018-5857-4A1E-8E04-56C4E120BB73Q34616822-5FDFCF64-53A2-49A3-B802-FBE182062171Q35013439-A9F08D36-18DF-48C6-882A-0A6E23638B20Q36014761-5E3D7048-084E-43EC-901A-126E6E592928Q36095048-25736B46-93D7-454F-91B9-70BD77D2EFA8Q36761839-644120D3-3B71-425D-9A9C-2F9EEE8895C0Q36856405-211657BB-5B8E-411F-B9CF-D3293CC86B68Q37426472-1341ECC4-B81E-4F45-87D1-447478E4EDDCQ37602169-4745C44D-B2F7-4708-B63B-5C131275F01AQ37714861-59D20CE9-B3F5-4286-8DA8-43253E877AF5Q37845667-A37DA505-6CCA-47A0-A20F-072378E9F49EQ38100295-DB876901-DEF3-4A1E-BE72-85757CD71583Q38441280-7C2233B8-0EEE-433D-BFD2-7815B6BEF7EFQ39340546-E5795ED5-A135-4F86-9CDD-76F69F2BD925Q39926048-CF46FE87-CC0A-4256-839C-1BDA4FEDF595Q41683448-27C7C8B6-B847-4B98-BE77-68A7A107C0A0Q41812981-7E798031-FBFA-4CBB-9C97-1C61C03CECBFQ43271983-DFA27851-2521-4FA5-B9CA-B2DF2D59313DQ55982486-24E73C44-14EA-4CF4-8633-9C3A73A2CC5B
P2860
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@ast
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@en
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@nl
type
label
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@ast
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@en
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@nl
prefLabel
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@ast
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@en
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@nl
P2093
P356
P1476
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
@en
P2093
P356
10.1136/JMG.2007.051177
P407
P577
2008-01-01T00:00:00Z